Understanding The Role of CYP17A1 in Drug Metabolism (G1586)

Target Name: CYP17A1

NCBI ID: G1586

CYP17A1

Understanding The Role of CYP17A1 in Drug Metabolism

CYP17A1, also known as cytochrome P450c17, is a gene that codes for a protein known as CYP17A1. This gene is located on chromosome 9 and is responsible for the production of a protein that plays a critical role in many cellular processes.

The CYP17A1 gene is a member of the cytochrome P450 gene family, which is a large family of enzymes that are involved in the metabolism of a wide variety of compounds. These enzymes are responsible for breaking down a wide range of drugs, including many statins, antidepressants, and other prescription and over-the-counter medications.

CYP17A1 is a key enzyme in the cytochrome P450 family, and it is involved in the metabolism of many different drugs. One of its main functions is to metabolize drugs that are taken to treat a wide range of conditions, including heart disease, diabetes, and mental health conditions.

One of the key challenges in the use of these drugs is that they can cause side effects, and some of these side effects can be severe. For example, some people taking statins may experience muscle pain, liver damage, or kidney damage. These side effects can be unpredictable and can vary from person to person.

CYP17A1 is also involved in the metabolism of many other drugs that are used to treat a wide range of conditions. For example, it is often used to metabolize antidepressants, which can cause side effects such as nausea, headache, and dizziness. It is also used to metabolize other drugs that are used to treat heart disease, such as beta blockers, calcium channel blockers, and ACE inhibitors.

In addition to its role in the metabolism of drugs, CYP17A1 is also involved in the regulation of many cellular processes. For example, it is involved in the production of sex hormones, which are essential for the development and maintenance of reproductive systems. It is also involved in the production of other hormones, such as insulin and growth hormone.

CYP17A1 is also involved in the regulation of the immune system. For example, it is involved in the production of cytokines, which are important for the immune response. It is also involved in the regulation of the production of antibodies, which are important for fighting off infections.

In addition to its role in the regulation of cellular processes, CYP17A1 is also involved in the metabolism of many different drugs. For example, it is often used to metabolize statins, which are drugs that are used to treat heart disease. CYP17A1 is also used to metabolize other drugs that are used to treat a wide range of conditions, such as diabetes and mental health conditions.

CYP17A1 is a key enzyme in the cytochrome P450 gene family and is involved in the metabolism of many different drugs. Its role in this process is critical for the safe and effective use of these drugs, and research is ongoing to better understand its mechanisms of action and its potential as a drug target.

In conclusion, CYP17A1 is a gene that codes for a protein that is involved in the metabolism of many different drugs. Its role in this process is critical for the safe and effective use of these drugs, and research is ongoing to better understand its mechanisms of action and its potential as a drug target. Further studies are needed to determine the full extent of its involvement in drug metabolism and its potential as a therapeutic target.

Protein Name: Cytochrome P450 Family 17 Subfamily A Member 1

Functions: A cytochrome P450 monooxygenase involved in corticoid and androgen biosynthesis (PubMed:9452426, PubMed:27339894, PubMed:22266943, PubMed:25301938). Catalyzes 17-alpha hydroxylation of C21 steroids, which is common for both pathways. A second oxidative step, required only for androgen synthesis, involves an acyl-carbon cleavage. The 17-alpha hydroxy intermediates, as part of adrenal glucocorticoids biosynthesis pathway, are precursors of cortisol (PubMed:9452426, PubMed:25301938) (Probable). Hydroxylates steroid hormones, pregnenolone and progesterone to form 17-alpha hydroxy metabolites, followed by the cleavage of the C17-C20 bond to form C19 steroids, dehydroepiandrosterone (DHEA) and androstenedione (PubMed:9452426, PubMed:27339894, PubMed:22266943, PubMed:25301938). Has 16-alpha hydroxylase activity. Catalyzes 16-alpha hydroxylation of 17-alpha hydroxy pregnenolone, followed by the cleavage of the C17-C20 bond to form 16-alpha-hydroxy DHEA. Also 16-alpha hydroxylates androgens, relevant for estriol synthesis (PubMed:27339894, PubMed:25301938). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:9452426, PubMed:27339894, PubMed:22266943, PubMed:25301938)

The "CYP17A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP17A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets